Drop us a note! We would love to hear from you.
Mendel has validated its clinical AI technology with third party statistical verification.
Mendel is the only company to validate outcomes with AI in a clinical setting.
UPDATES & NEWS — 2 MIN READ
Mendel.ai is improving identification of suitable cancer patients and matching to clinical trials. Mendel.ai, a US-based company founded in 2016, uses AI tools to analyse clinical data, including medical history and genetic analysis, from cancer patients. Its goal is to facilitate clinical trials in oncology research by organising and analysing RWD, and matching patients to the right clinical trials.45 They take medical data from many structured and unstructured data sets and turn these into data digitised patient journeys aligned to specific treatments. Having collected data on over 1 million journeys, its algorithm can segment patient populations by their demographic, such as how African American women with breast cancer respond to a particular drug. In essence creating in silico or patient-less trials. The AI algorithm built on these data helps trial recruitment by finding eligible patients.
PODCAST — 26 minutes
John is an experienced early-stage investor, focusing on companies across frontier technology, enterprise software, robotics, healthcare, and artificial intelligence. He gravitates towards startups that are using science and technology to break down barriers to productivity growth and enable a better future for the largest number of people.
PODCAST — 33 minutes
Jason LaBonte is an executive with over 15 years of experience in leading healthcare information companies. Accomplished manager at all levels, including analyst and production staff, product management and product development teams, and executive teams.
PODCAST — 23 minutes
Mark Goldstein is a full-time investor and advisor, he runs a lit' seed fund and he is a partner at a Series A venture fund. He is also a Founder of UCSF Health Hub, UCSF's growth studio.
PODCAST — 32 minutes
Melisa Tucker, VP Product Management & Operations, Real World Evidence at Flatiron Health was our guest on Patientless Podcast.
PODCAST — 27 minutes
Today's guest is Dr. Richard Gliklich, he's the founder and CEO of OM1, but he's also a physician. He's a professor of Otolaryngology at Harvard medical school, and before starting OM1 he also founded a company called Outcome at around 1998. That was eventually sold to what is now known as IQVIA, and built the phase four or the outcome piece of the business. He has led several key national and international efforts focused on evaluating the safety and effectiveness and value and quality of healthcare. So we're very honored to have him today on our podcast. Richard, thank you so much and welcome to the Patientless podcast.
PODCAST — 40 minutes
Our guest is Jacob LaPorte, Co-Founder & Global Head of The BIOME by Novartis | Co-Founder/Advisor of digital health start-ups.
PODCAST — 44 minutes
Welcome to the first episode of Mendel's Patientless Podcast. Our first guest is Brent Clough, CEO of Trio Health. Brent started his career in the financial sector. He was a VP at Goldman Sachs; founded a very interesting company in healthcare: IntrinsiQ, which pretty much build the largest longitudinal patient database at the time and was later acquired. Brent is now a co-founder of Trio.
VIDEO — 8 minutes
Mendel's CEO Karim Galil was a guest in Hospital-to-Home by UCSF Health Hub. Karim presented how Mendel transforms EMR data and clinical literature.
Interview — 25 min
Mendel's CEO Karim Galil was a guest in Bootstrap Lab's Applied AI Insiders Series. Karim talked about race to a COVID-19 Vaccine using AI.
UPDATES & NEWS — 2 MIN READ
We’re now excited to announce our new COVID-19 AI search engine which is available to the public here. Mendel ingested and absorbed more than 50,000 scholarly articles, released by the White House, related to Coronaviruses and COVID-19. Researchers, epidemiologists, and clinicians can use this tool to ask questions about COVID-19 and glean relevant answers in seconds — a process that can take a human numerous hours, days, or even weeks to conduct.
Researcher using Mendel’s COVID-19 search engine found evidence that hypertension drug Diltiazem may halt virus replication.
PODCAST – 1.30 H
Welcome to the first episode of Mendel's "Beyond the Data" podcast. Our first guest is Janak Joshi, Senior Vice President, Chief Technology Officer and Head of Strategy at LifeImage. Throughout his career, Janak Joshi has been at the cutting edge of science, health and technology. At Life Image, he is focused on building industry-leading products for researchers, engineers and clinicians within a global footprint. He is a three-time entrepreneur successfully raising capital, and building and selling companies with the mission of leaving a legacy to prove that our generation did indeed fix healthcare in the U.S. Janak currently serves a Board Member of Bentley Venture Capital Funds one of the judges for MassChallenge and is an advisor to early stage start-ups in the bio-pharmaceutical and healthcare IT space. He continues to serve with pride in the U.S.A.F. Search & Rescue Squadron 1001st-PA as a 1st Lt. Podcast is hosted by Karim Galil, CEO of Mendel.
